LPS challenge in healthy subjects: An investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2
Highlights
► LPS inhalation in healthy subjects increases the levels of CXCL8 but not CXCL1. ► LPS inhalation also increases the chemotactic capacity of sputum supernatant. ► Chemotactic capacity inhibited more using a dual CXCR1/CXCR2 antagonist. ► TLR4 signalling causes airway neutrophilia dependent on CXCL8 driven chemotaxis. ► Supports development of dual CXC1/CXCR2 antagonists for neutrophilic lung diseases
Introduction
Chronic obstructive pulmonary disease (COPD) and severe asthma are characterised by an increase in the number of neutrophils in the airways [1], [2], [3]. Neutrophils contribute to a persistent and abnormal innate immune response in these diseases, by releasing pro-inflammatory cytokines and tissue destructive proteases. Neutrophils are recruited into the lungs by chemokines such as CXCL1 (GROα) and CXCL8 (IL-8) that act through the cell surface chemokine receptors CXCR1 and CXCR2 [4]. Both CXCL1 and CXCL8 levels are increased in the airways of patients with asthma and COPD [5], [6], [7], [8], [9]. CXCL8 binds to both CXCR1 and CXCR2 [4]. In contrast, CXCL1 acts only through CXCR2 [10].
Antagonists targeted selectively against CXCR2 have been developed for the treatment of neutrophilic airway inflammation [11]. Dual antagonists targeted against both CXCR1 and CXCR2 may have a greater effect on neutrophil chemotaxis due to the additional targeting of CXCR1. Furthermore, CXCR1 is involved in neutrophil activation as well as chemotaxis [12]. It has been shown in different studies that both the selective CXCR2 antagonist SB656933 and the dual CXCR1/CXCR2 antagonist Sch527123 inhibit ozone induced airway neutrophilia in healthy subjects [13], [14].
Toll‐like receptors (TLRs) act as sensors for pathogen associated microbial peptides [15]. TLR4 is expressed on a range of structural and immune cell types, and acts as a receptor for the bacterial endotoxin lipopolysaccharide (LPS) [16]. TLR4 signals through the nuclear factor kappa-light-chain-enhancer of activated B cells (NFKB) pathway and mitogen activated protein kinases (MAPK) to increase pro-inflammatory cytokine production [17]. Patients with asthma and COPD often suffer with acute and chronic bacterial infections that can amplify the innate immune response through TLR4 signalling [18]. The inhalation of LPS in healthy subjects increases the number of airway neutrophils, which is easily measured in induced sputum samples [19], [20], [21],. This model has been used to study the mechanisms of neutrophilic lung diseases [22], [23].
In vitro studies of neutrophil chemotaxis often use single chemokines as the chemoattractant [24]. Such systems do not resemble the in vivo environment containing multiple chemoattractants. Induced sputum supernatants obtained after LPS challenge in healthy subjects contain multiple chemoattractants [21], and so may be a more clinically relevant model to study chemotaxis mechanisms compared to single chemokine systems. Chemotaxis using induced sputum after LPS challenge has not been used before, and could be utilised to investigate the roles of CXCL1 and CXCL8, and their receptors CXCR1 and CXCR2 using clinically relevant chemotaxis signals.
We have used the inhaled LPS model in healthy subjects to investigate mechanisms of neutrophil chemotaxis into the airways. We studied the effect of LPS challenge on CXCL1 and CXCL8 levels in sputum supernatants, and whether LPS challenge increased the chemotactic ability of these supernatants. The roles of CXCR1 and CXCR2 in neutrophil chemotaxis caused by sputum supernatants obtained after LPS challenge were investigated by using the selective CXCR2 antagonist SB656933 and the dual CXCR1 and CXCR2 antagonist Sch527123.
Section snippets
Subjects
Fourteen healthy subjects (7 males and 7 females, mean age 33.7 years) were recruited, who had no history of smoking and had normal lung function. Exclusion criteria were: a respiratory tract infection in previous six weeks, positive skin prick test to grass, cat or house dust mite and history of chronic respiratory disease. Written informed consent was obtained and the local ethics committee approved the study.
Safety
LPS challenges were performed safely in 14 subjects, with only minor adverse events reported: headache (n = 5), myalgia (n = 1) and flu like symptoms (n = 1). All of these symptoms were resolved within 24 h. None of the subjects complained of breathlessness or wheezing during the study. Body temperature was significantly increased at 4–8 h post‐LPS inhalation with a maximum mean rise of 0.8 °C at 8 h, which had returned to normal by 24 h (Fig. 1A). The mean maximum fall in FEV1 was 5.1% (Fig. 1B). There
Discussion
We have used an in vivo model of human lung inflammation to investigate the roles of CXCL1 and CXCL8 and their receptors CXCR1 and CXCR2 in the development of pulmonary neutrophilia. We observed that LPS inhalation in healthy subjects increased the levels of CXCL8 but not CXCL1. LPS inhalation also increased the chemotactic capacity of sputum supernatant, which was more effectively inhibited using a dual CXCR1 and CXCR2 antagonist (Sch527123) compared to a selective CXCR2 antagonist (SB656933).
Conclusion
In conclusion, we have demonstrated that LPS increases neutrophil chemotaxis that appears to be driven by CXCL8 signalling rather than CXCL1. This increase in CXCL8 levels was closely associated with increased chemotaxis. Pharmacological antagonism in both CXCR1 and CXCR2 was more effective in blocking chemotaxis than antagonism of CXCR2 alone. These results support the further development of dual CXC1 and CXCR2 antagonists against neutrophilic lung diseases.
Abbreviations
- LPS
Lipopolysaccharide
- MAPK
Mitogen activated protein kinases
- IL-6
Interleukin 6
- MSD
Meso scale discovery
- TLR
Toll-like receptor
- NFKB
Nuclear factor kappa-light-chain-enhancer of activated B cells
- COPD
Chronic obstructive pulmonary disease
- FEV1
Forced expiratory volume in 1 second
- PBS
Phosphate buffered saline
- RT
Room temperature
- NGS
Normal goat serum
- IgG
Immunoglobulin
- DAB
3,3′‐diaminobenzidine
- PMN
Polymorphonuclear leukocytes
- EDTA
Ethylenediaminetetraacetic acid
- HBSS
Hanks balanced salt solution
- BSA
Bovine serum albumin
- DMSO
Competing interests
RA and JP, have no conflicts of interest to disclose. SP, SS and IK are employees of Pfizer. DS has received sponsorship to attend international meetings, honoraria for lecturing or attending advisory boards, and research grants from various pharmaceutical companies including AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Almirall, Forest, Pfizer, UCB, Novartis, and Cipla.
Funding
This work was supported by Pfizer Global R&D, Sandwich, Kent, UK.
References (33)
- et al.
Airway inflammation in COPD assessed by sputum levels of interleukin-8
Chest
(1997) - et al.
Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease
Respir Med
(2006) Chemokine receptors in airway disease: which receptors to target?
Pulm Pharmacol Ther
(2001)- et al.
Pathogen recognition and innate immunity
Cell
(2006) - et al.
Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human
Pulm Pharmacol Ther
(2007) - et al.
CXCR2 antagonists for the treatment of pulmonary disease
Pharmacol Ther
(2009) - et al.
Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils
Thorax
(1996) - et al.
Neutrophilic inflammation in severe persistent asthma
Am J Respir Crit Care Med
(1999) - et al.
Inflammatory biomarkers in airways of patients with severe asthma compared with non-severe asthma
Clin Exp Allergy
(2009) - et al.
Interleukin-8 and related chemotactic cytokines—CXC and CC chemokines
Adv Immunol
(1994)
Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma
Am J Respir Crit Care Med
Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD
Thorax
Bronchial mucosal inflammation and upregulation of CXC chemoattractants and receptors in severe exacerbations of asthma
Thorax
Human chemokines: an update
Annu Rev Immunol
Different functions for the interleukin 8 receptors (IL-8R) of human neutrophil leukocytes: NADPH oxidase and phospholipase D are activated through IL-8R1 but not IL-8R2
Proc Natl Acad Sci U S A
SB-656933, a novel CXCR2 selective antagonist, inhibits ex-vivo neutrophil activation and ozone-induced airway inflammation in humans
Br J Clin Pharmacol
Cited by (29)
Steroid sparing effects of doxofylline
2018, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :Since doxofylline has been demonstrated to have anti-inflammatory activity [12] and to show significant clinical benefit in both adults and children with asthma or COPD, we have investigated whether doxofylline can exhibit corticosteroid sparing activity in murine models of non-allergic (LPS) and allergen-induced leukocyte infiltration into the lung. We have utilised bacterial LPS as the model for non allergic leukocyte infiltration as this is known to be a good stimulus to induce neutrophil recruitment into the lung, both experimentally [17,18] and clinically [19–21], and we have used a well established model of allergic inflammation in the airways to investigate whether doxofylline can have corticosteroid sparing activity against allergen-induced eosinophil infiltration into the lungs of mice. Male and female BALB/c mice, 6–8 weeks old, were used in this study (Envigo, UK).
Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation
2015, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :Although the relative contribution of CXCL8 vs. other chemokines acting on CXCR1/2 to pathology in pulmonary diseases is unknown, human pharmacology studies suggest an important role of CXCL8 and CXCR1 in neutrophil migration to the lung. In this sense our results are in line with the data published by Aul et al. showing that LPS-induced neutrophil chemotaxis in sputum of healthy volunteers was inhibited by 79% with SCH527123 as compared to 52% with SB656933 [22]. In addition, conditioned media from stimulated COPD alveolar macrophages highlighted the relevance of CXCL8 as the main driver of neutrophil migration and confirmed that a dual CXCR1/2 therapy blocked neutrophil migration more efficiently than a selective CXCR2 treatment [23].
Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability
2015, Bioorganic and Medicinal Chemistry LettersDoxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse
2014, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :In this study, we have investigated the effect of doxofylline on an inflammatory response induced by LPS in the lung of BALB/c mice. We show that treatment with 0.3 and 1, but not 0.1 mg/kg, of doxofylline significantly inhibited the migration of neutrophils and the release of IL-6 and TNF-α into the lung lumen, demonstrating the anti-inflammatory action of doxofylline in this model of inflammation that has been widely used to evaluate anti-inflammatory activity of various drug classes (Fig. 1A and B) [12–14]. As expected, mice treated with LPS showed a significant decrease in the number of leukocytes present in the bone marrow when compared to the saline-treated group, reflecting a greater mobilization of these cells into the circulation in response to this inflammatory stimulus.
Altered lung function relates to inflammation in an acute LPS mouse model
2012, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :The application of imaging techniques such as non-invasive proton (1H) and invasive helium (3He) MRI can further validate and strengthen our results in this model [8,17,30]. In the clinics, inhalation of LPS in healthy volunteers has been used to model acute exacerbations of COPD and to investigate the effects of anti-inflammatory drugs [2,3,38,39]. Our results support several key findings in these studies, where inflammation is characterised by early neutrophilic infiltration to lung tissue and BALF, followed by macrophages and lymphocytes, and a reduction in FEV1, FVC and PEF rates [2,40].
- 1
Raminder Aul and Sheena Patel contributed equally to this work and are joint first authors.